Novo Nordisk A/S (NVO)
NYSE: NVO · Real-Time Price · USD
74.01
0.00 (0.00%)
At close: Jun 18, 2025, 4:00 PM
73.80
-0.21 (-0.28%)
Pre-market: Jun 20, 2025, 6:43 AM EDT
Novo Nordisk Revenue
Novo Nordisk had revenue of 78.09B DKK in the quarter ending March 31, 2025, with 19.49% growth. This brings the company's revenue in the last twelve months to 303.14B, up 24.11% year-over-year. In the year 2024, Novo Nordisk had annual revenue of 290.40B with 25.03% growth.
Revenue (ttm)
303.14B DKK
Revenue Growth
+24.11%
P/S Ratio
7.58
Revenue / Employee
3,919,133 DKK
Employees
77,349
Market Cap
333.14B USD
Revenue Chart
* This company reports financials in DKK.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 290.40B | 58.14B | 25.03% |
Dec 31, 2023 | 232.26B | 55.31B | 31.26% |
Dec 31, 2022 | 176.95B | 36.15B | 25.68% |
Dec 31, 2021 | 140.80B | 13.85B | 10.91% |
Dec 31, 2020 | 126.95B | 4.93B | 4.04% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Abbott Laboratories | 42.34B |
NVO News
- 1 day ago - U.S. judge upholds FDA's removal of Ozempic, Wegovy from drug shortage list - Reuters
- 4 days ago - Novo Nordisk: The Strength To Withstand Challenges - Seeking Alpha
- 4 days ago - The story of how Novo Nordisk will lose billions because it didn't pay a couple of hundred dollars - Market Watch
- 6 days ago - Novo Nordisk Is Europe's Most Valuable Company—Again. Eli Lilly, Watch Out. - Barrons
- 7 days ago - Novo Nordisk regains crown as Europe's most valuable company - Reuters
- 7 days ago - After ousting CEO, Novo Nordisk reclaims crown as largest European company - Market Watch
- 7 days ago - Novo Nordisk plans to start late-stage trials for experimental obesity drug amycretin - Reuters
- 7 days ago - Novo Nordisk to advance subcutaneous and oral amycretin for weight management into phase 3 clinical development - GlobeNewsWire